Optimization of medical care for patients with hepatic cirrhosis and analysis of typical mistakes in their management tactics


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Complications of hepatic cirrhosis (HC) and the associated mortality are potentially preventable. Timely diagnosis of HC, the development and widespread implementation of algorithms for maintaining this complex population of patients that meet the standards and national clinical guidelines will help reduce the mortality from digestive diseases. Objective. Optimization of medical care for patients with hepatic cirrhosis (HC) based on an analysis of systemic mistakes in the management tactics for this group of patients in real clinical practice. Methods. 523 medical records of HC patients who received medical care in an outpatient and inpatient settings and who died of HC in the areas of the Krasnodar Territory in 2015-2019 were examined. Results. A number of systemic mistakes in the management tactics for this group of patients were identified and analyzed; authors’ own experience and literature data on the elimination of identified defects are presented. Conclusion. Optimization of the quality of medical care for HC patients can be reached by a multidisciplinary approach involving physicians, gastroenterologists, infectious disease specialists, narcologists, nutritionists, surgeons, endoscopists, and physical therapy specialists. The main line of work with this group of patients is the timely detection of HC at the stage of compensation, etiological treatment, prevention and timely treatment of HC complications.

Full Text

Restricted Access

About the authors

Natalia V. Korochanskaya

Kuban State Medical University; Regional Clinical Hospital № 2

Email: nvk-gastro@mail.ru
Dr. Sci. (Med.), Head of the astroenterological Center, City Clinical Hospital № 2; Professor at the Department of Surgery № 3 FATPRS, Kuban State Medical University Krasnodar, Russia

V. M Durleshter

Kuban State Medical University; Regional Clinical Hospital № 2

Department of Surgery № 3 FATPRS Krasnodar, Russia

O. V Kovalevskaya

Regional Clinical Hospital № 2

Krasnodar, Russia

S. N Serikova

Kuban State Medical University; Regional Clinical Hospital № 2

Department of Surgery № 3 FATPRS Krasnodar, Russia

M. A Basenko

Kuban State Medical University

Krasnodar, Russia

References

  1. Backus L.I., Boothroyd D.B., Phillips B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-16. doi: 10.1016/j.cgh.2011.03.004.
  2. Kanwal F., Kramer J., Asch S.M., et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-1005. Doi: 10.1053/j. gastro.2017.06.012.
  3. Liaw Y.F, Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31. doi: 10.1056/NEJMoa033364.
  4. Fuster D., Samet J.H. Alcohol use in patients with chronic liver disease. N Engl J Med. 2018;379(26):2579. Doi: 10.1056/ NEJMc1814129.
  5. Kanwal F.,Volk M., Singal A., et al. Improving qualityof health care for patients with cirrhosis. Gastroenterology 2014;147:1204-47. doi: 10.1053/j.gastro.2014.10.029.
  6. Gins P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7(1):122-28. Doi: 10.1002/ hep.1840070124.
  7. DAmico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180-93. doi: 10.1111/apt.12721.
  8. DAmico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-31. Doi: 10.1016/j. jhep.2005.10.013
  9. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печении Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологиии, гепатологии и колопроктолоогии. 2016;26(4):71-102.
  10. Iwasa M., Iwata K., Hara N., et al. Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition. 2013;29(11-12):1418-21. Doi: 10.1016/]. nut.2013.05.016.
  11. Plank L.D., Gane E.J., Peng S., et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557-66. doi: 10.1002/hep.22367.
  12. Gluud L.L., Krag A. Banding ligation versus betablockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev. 2012;(8):CD004544. doi: 10.1002/14651858. CD004544.pub2.
  13. Ge P.S., Runyon B.A. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(21):2104-105. doi: 10.1056/NEJMc1612334.
  14. Alberino F., Gatta A., Amodio P., et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17(6):445-50. doi: 10.1016/s0899-9007(01)00521-4
  15. Montano-Loza A.J., Meza-Junco J., Prado C.M., et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166- 73. 173.e1. Doi: 10.1016/]. cgh.2011.08.028.
  16. Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979-85. Doi: 10.1016/j. cgh.2010.06.024
  17. Merli M., Giusto M., Lucidi C., et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2013;28(2):281-84. doi: 10.1007/s11011-012-9365-z.
  18. Huisman E.J., Trip E.J., Siersema P.D., et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23(11):982-89. Doi: 10.1097/ MEG.0b013e32834aa4bb.
  19. Merli M., Berzigotti A., Zelber-Sagi S., et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172-93. doi: 10.1016/j.jhep.2018.06.024.
  20. Berzigotti A., Saran U., Dufour J.F. Physical activity and liver diseases. Hepatology 2016;63(3):1026-40. doi: 10.1002/hep.28132
  21. European Association for the Study of the Liver; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018;69:406-60. doi: 10.1016/j.jhep.2018.03.024.
  22. Tsien C.D., Rabie R., Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131-37. doi: 10.1136/gutjnl-2011-301255.
  23. Garcia-Tsao G., Abraldes J.G., Berzigotti A., Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-35. doi: 10.1002/hep.28906.
  24. Pagliaro L., D'Amico G., Pasta L., et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann RJ, eds. Portal Hypertension: Pathophysiology and Treatment. Oxford, UK: Blackwell Scientific. 1994. P 72-92.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies